Clinical trial · Observational
Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker
Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls. The main questions it aims to answer are: * To create a biobank with samples of human body material (HBM): blood (serum/plasma/DNA) and tissue and clinical data of patients with cutaneous melanoma, non-melanoma and helathy controls. * To support future research questions (after specific approval of the Ethics Committee) by using the biobank (through satellite protocols). If there is a comparison group: Not applicable (umbrella protocol for collection only). Participants will: * Share demographics, medical and surgical history, risk factors. * Complete Cancer Worry Scale questionnaire. * Provide biological samples: * Blood samples (serum, plasma, DNA). * Tissue samples (residual tissue or additional biopsy if consented).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Skin Cancer Melanoma | — | UNRESOLVED | — |
| Skin Cancer, Non-Melanoma | Skin Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collection of Human Body Material and Clinical Data | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Biobank Collection Arm
- description
- Participants diagnosed with cutaneous melanoma or non-melanoma skin cancer or healthy controls will provide informed consent for collection and long-term storage of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and associated clinical data for future research.
- interventionNames
- Other: Collection of Human Body Material and Clinical Data
Primary outcomes (1)
- measure
- Establishment of a biobank of human body material (HBM) and clinical data
- timeFrame
- Baseline (diagnosis and informed consent) through study completion, approximately 10 years.
- description
- Successful prospective collection and long-term storage of blood (serum, plasma, DNA), tissue samples, and associated clinical data from patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls.
Secondary outcomes (1)
- measure
- Availability of biobank resources for future research
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * Adult subjects (\>18 years of age) at time of enrolment. * Subjects diagnosed with cutaneous melanoma, Non-melanoma skin cancer or healthy controls. * Adult subjects able and willing to provide informed consent. Exclusion Criteria: * Subjects unable or not willing to provide informed consent. * Pregnancy (or willing to become pregnant) is NOT an exclusion criteria (unless specified in the respective satellite protocols.
References
Publications (0)
Data not yet available